<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03172533</url>
  </required_header>
  <id_info>
    <org_study_id>UKER-AN-HS-01</org_study_id>
    <nct_id>NCT03172533</nct_id>
  </id_info>
  <brief_title>Estrogen Replacement in Anorexia Nervosa</brief_title>
  <acronym>HOSAN</acronym>
  <official_title>Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial on the Effects of an Estrogen-progestin Combination as add-on to Inpatient Psychotherapy in Adult Female Patients Suffering From Anorexia Nervosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Erlangen-Nürnberg Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Erlangen-Nürnberg Medical School</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is a placebo-controlled randomised study on the effects of estrogen&#xD;
      replacement upon AN-associated psychopathology, several neurocognitive domains and&#xD;
      appetite-regulating circuits in female patients with AN.&#xD;
&#xD;
      The investigators aim at assessing peripheral concentrations of neuroendocrinological&#xD;
      components of the Hypothalamus-Pituitary-Gonadal (HPG) and Hypothalamus-Pituitary-Adrenal&#xD;
      (HPA) axis, as well as appetite-regulating hormones in AN and to examine associations with&#xD;
      AN-associated psychopathology and neurocognitive performances before (baseline), during and&#xD;
      after inpatient psychotherapy of female patients receiving concomitant treatment with&#xD;
      estrogens (vs. placebo).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While there is broad knowledge on the disruption of appetite regulation, neurocognitive&#xD;
      deficits in AN patients, the impact of cortisol on neurocognitive performances in patients&#xD;
      with AN and the effects of estrogen on neurocognitive features in healthy subjects, up to&#xD;
      now, no study has implemented estrogen replacement in AN patients, in order to examine ist&#xD;
      effects upon AN-associated psychopathology, neurocognition and peptides regulating appetite.&#xD;
      Thus, this is the first study of its kind.&#xD;
&#xD;
      Primary target: Assessment of the impact of sexual hormone replacement using an&#xD;
      estrogen-progestin-combination as add-on to psychotherapy upon neurocognitive performance in&#xD;
      patients suffering from anorexia nervosa by means of a neuropsychological test battery&#xD;
      consisting of a test of verbal intelligence, the Trail making test A and B, a Go/No-go&#xD;
      paradigm and the Wisconsin Card Sorting Test.&#xD;
&#xD;
      Secondary targets:&#xD;
&#xD;
        -  Examination of safety and tolerability of sexual hormone replacement using an&#xD;
           estrogen-progestin-combination in patients with anorexia nervosa.&#xD;
&#xD;
        -  Assessment of the impact of the sexual hormone replacement upon psychopathology in&#xD;
           patients with anorexia nervosa by means of the Eating Disorder Examination Questionnaire&#xD;
           (EDE-Q) and the Eating Disorder Inventory-2 (EDI-2).&#xD;
&#xD;
        -  Assessment of the impact of substitution upon anxiety (STAI)&#xD;
&#xD;
        -  Assessment of the impact on cortisol levels&#xD;
&#xD;
        -  Assessment of the impact on appetite-regulating plasma peptides&#xD;
&#xD;
        -  Assessment of the impact on the prescription of antidepressants&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulties in recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">March 15, 2016</start_date>
  <completion_date type="Actual">January 15, 2019</completion_date>
  <primary_completion_date type="Actual">January 15, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized, placebo-controlled Phase IIa clinical trial in patients with anorexia nervosa</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-blinded study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in neurocognitive performance</measure>
    <time_frame>10 weeks of hormonal substitution with an estrogen-progestin-combination</time_frame>
    <description>Performance based on a neurocognitive test battery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse Events (AE) (safety/tolerability)</measure>
    <time_frame>10 weeks of hormonal substitution with an estrogen-progestin-combination</time_frame>
    <description>Number of adverse events (including AE, AR, severe AE, SAR and SUSAR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in psychopathology (EDE-Q)</measure>
    <time_frame>10 weeks of hormonal substitution with an estrogen-progestin-combination</time_frame>
    <description>Changes in sum scores in the EDE-Q</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in psychopathology (EDI-2)</measure>
    <time_frame>10 weeks of hormonal substitution with an estrogen-progestin-combination</time_frame>
    <description>Changes in sum scores in the EDI-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in psychopathology (STAI)</measure>
    <time_frame>10 weeks of hormonal substitution with an estrogen-progestin-combination</time_frame>
    <description>Changes in sum scores in the STAI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in psychopathology (Patient Health Questionnaire-9, PHQ-9)</measure>
    <time_frame>10 weeks of hormonal substitution with an estrogen-progestin-combination</time_frame>
    <description>Changes in sum scores in the PHQ-9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in psychopathology (Eating Disorder Quality of Life, EDQoL)</measure>
    <time_frame>10 weeks of hormonal substitution with an estrogen-progestin-combination</time_frame>
    <description>Changes in sum scores in the EDQoL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuroendocrinological changes (cortisol)</measure>
    <time_frame>10 weeks of hormonal substitution with an estrogen-progestin-combination</time_frame>
    <description>Changes in plasma cortisol levels during a dexamethasone suppression test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuroendocrinological changes (glucose)</measure>
    <time_frame>10 weeks of hormonal substitution with an estrogen-progestin-combination</time_frame>
    <description>Changes in plasma concentrations of glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuroendocrinological changes (insulin)</measure>
    <time_frame>10 weeks of hormonal substitution with an estrogen-progestin-combination</time_frame>
    <description>Changes in plasma concentrations of insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuroendocrinological changes (ghrelin)</measure>
    <time_frame>10 weeks of hormonal substitution with an estrogen-progestin-combination</time_frame>
    <description>Changes in plasma concentrations of the appetite-regulating peptide ghrelin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuroendocrinological changes (leptin)</measure>
    <time_frame>10 weeks of hormonal substitution with an estrogen-progestin-combination</time_frame>
    <description>Changes in plasma concentrations of the appetite-regulating peptide leptin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in antidepressant medication</measure>
    <time_frame>10 weeks of hormonal substitution with an estrogen-progestin-combination</time_frame>
    <description>Changes in antidepressants´ use</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Anorexia Nervosa</condition>
  <arm_group>
    <arm_group_label>verum group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>approved oral contraceptive: ethinyl estradiol 0.03mg and dienogest 2mg (combination drug) daily intake over 10 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ethinyl estradiol 0.03mg and dienogest 2 mg (combination)</intervention_name>
    <description>approved oral contraceptive (Germany): Maxim</description>
    <arm_group_label>verum group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>placebo</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  anorexia nervosa according to the Diagnostic and Statistical Manual of Mental&#xD;
             Disorders (DSM V) or subsyndromal anorexia nervosa (lack of a diagnostic symptom&#xD;
             according to DSM V)&#xD;
&#xD;
          -  BMI ≥ 13 kg/m2 and ≤ 18.5 kg/m2&#xD;
&#xD;
          -  able to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  a known hypersensitivity to the active compound or to other components of the study&#xD;
             drug&#xD;
&#xD;
          -  one or more contraindications for the use of hormonal contraception: Smoking over 20&#xD;
             cigarettes/day; Acute venous thromboembolic disease or increased risk; Known&#xD;
             hereditary or acquired predisposition for venous thrombosis, e.g. activated protein C&#xD;
             (APC)-resistance (including factor V Leiden Mutation), antithrombin III deficiency,&#xD;
             protein C deficiency, protein S deficiency; Risk for arterial thromboembolism&#xD;
             (diabetes mellitus with vascular sequelae, severe hypertonus, severe&#xD;
             dyslipoproteinemia); Known hereditary or acquired predisposition for arterial&#xD;
             thrombosis, e.g. hyperhomocysteinemia and anti-phospholipid antibodies&#xD;
             (anticardiolipin antibodies, Lupus anticoagulants); Cerebrovascular disease (past&#xD;
             cerebral infarction or prodromal states such as transitory ischemia attacks); Past&#xD;
             migraine with focal neurological symptoms; Liver disease or pancreatitis;&#xD;
             Dubin-Johnson syndrome and Rotor syndrome; Known porphyria; Known or suspected sexual&#xD;
             hormone sensitive tumors; Unresolved vaginal bleeding&#xD;
&#xD;
          -  a present severe depressive episode (major depression) according to the DSM V&#xD;
&#xD;
          -  past or present alcohol or drug abuse&#xD;
&#xD;
          -  severe psychiatric disorders (axis I) according to the DSM V (such as bipolar&#xD;
             affective disorder or schizophrenia) in addition to anorexia nervosa&#xD;
&#xD;
          -  suicidality&#xD;
&#xD;
          -  known diabetes mellitus&#xD;
&#xD;
          -  severe somatic comorbidity or organ dysfunction that is not compatible with intake of&#xD;
             the study drug&#xD;
&#xD;
          -  use of hormonal depot compounds (injectable drugs, implants), or hormonal intrauterine&#xD;
             pessaries during the last four weeks before the screening visit (V1)&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  breastfeeding during the last 6 months before V1&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Psychosomatic Medicine and Psychotherapy, University Hospital Erlangen</name>
      <address>
        <city>Erlangen</city>
        <state>Bavaria</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>May 22, 2017</study_first_submitted>
  <study_first_submitted_qc>May 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2017</study_first_posted>
  <last_update_submitted>January 28, 2019</last_update_submitted>
  <last_update_submitted_qc>January 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anorexia nervosa</keyword>
  <keyword>estrogen</keyword>
  <keyword>psychotherapy</keyword>
  <keyword>cortisol</keyword>
  <keyword>appetite regulation</keyword>
  <keyword>neurocognitive performance</keyword>
  <keyword>eating disorder</keyword>
  <keyword>sexual hormone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anorexia</mesh_term>
    <mesh_term>Anorexia Nervosa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dienogest</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

